Mereo BioPharma Group plc
MREO evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for MREO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · MREO
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing innovative therapeutics for rare diseases, with a lead pipeline targeting unmet medical needs and a cash runway projected into late 2027.
Key risk: Financing risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$40.3M
Cash Runway
—
Lead Asset
alvelestat (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates for Mereo BioPharma Group plc.
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing innovative therapeutics for rare diseases, with a lead pipeline targeting unmet medical needs and a cash runway projected into late 2027.
- Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases [sec_mda · as of 2026-08-11].
- As of December 31, 2025, the company had an accumulated deficit of $501.0 million [sec_mda · as of 2026-03-19].
- The company expects its current cash resources to extend into late 2027, but will need additional external funding to complete development plans and commercialize products [sec_mda · as of 2026-08-11].
- Net income for the latest reported period (as of 2026-06-30) was -$7.0 million [sec].
- The company expects to continue incurring significant operating losses for the foreseeable future as it advances research, development, and regulatory efforts [sec_mda · as of 2026-03-19].
What works
- The company has a clear focus on rare diseases, a sector with high unmet need and potential for regulatory incentives [sec_mda · as of 2026-08-11].
- Management anticipates that current cash on hand will fund operations into late 2027, providing a multi-year development runway [sec_mda · as of 2026-08-11].
- The company is listed on Nasdaq, providing access to U.S. capital markets for future funding [sec_mda · as of 2026-08-11].
What to weigh
- The company has an accumulated deficit of $501.0 million as of December 31, 2025, reflecting a history of losses [sec_mda · as of 2026-03-19].
- Mereo BioPharma will need additional external funding to complete its development plans and potentially commercialize products, creating financing risk [sec_mda · as of 2026-08-11].
- The company expects to continue reporting significant operating losses for the foreseeable future [sec_mda · as of 2026-03-19].
From the filings
Quoted directly from source documents.
Company focus on rare diseases
“We are a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases.”
SEC MD&A · August 11, 2026
Accumulated deficit as of Dec 31, 2025
“As of December 31, 2025, we had an accumulated deficit of $501.0 million.”
SEC MD&A · March 19, 2026
Cash runway into late 2027
“we anticipate that our current on-hand cash resources will extend into late 2027.”
SEC MD&A · August 11, 2026
Need for additional external funding
“we will need additional external funding to complete our development plans and potentially commercialize selected rare disease products.”
SEC MD&A · August 11, 2026
Risks & what to watch (3)›
Key risks
- Financing risk — The company will need additional external funding to complete development and commercialization plans [sec_mda · as of 2026-08-11].
- History of losses — Accumulated deficit of $501.0M as of Dec 31, 2025, with expected continued losses [sec_mda · as of 2026-03-19].
- Regulatory and clinical risk — Development and regulatory approval of product candidates is uncertain and may face delays or failures [sec_mda · as of 2026-08-11].
What to watch
- Progress of clinical trials for rare disease product candidates [sec_mda · as of 2026-08-11].
- Ability to secure non-dilutive or equity financing to extend runway beyond late 2027 [sec_mda · as of 2026-08-11].
- Regulatory milestones and potential approval decisions for lead candidates [sec_mda · as of 2026-08-11].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Mereo BioPharma Group plc through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Mereo BioPharma Group plc facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$7M
Lead: Phase 3
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
58
Total value held
$11.7M
| Holder | Shares | Value |
|---|---|---|
| 683 capital management, llc | 12,000,000 | $4.0M |
| bank of america corp /de/ | 8,195,287 | $2.7M |
| newtyn management, llc | 7,079,056 | $2.3M |
| millennium management llc | 3,559,103 | $1.2M |
| marshall wace, llp | 686,987 | $227K |
| citadel advisors llc | 454,800 | $150K |
| susquehanna international group, llp | 443,920 | $146K |
| group one trading llc | 335,827 | $111K |
| jane street group, llc | 333,773 | $110K |
| rangeley capital, llc | 329,200 | $109K |
Showing top 10 of 58 institutional holders of Mereo BioPharma Group plc. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 6.4%
- Days to cover
- 5.3
- Shares short
- 8,267,481
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
MREO short interestGovernance
Frequently asked questions
What is the AI investment thesis for Mereo BioPharma Group plc?
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing innovative therapeutics for rare diseases, with a lead pipeline targeting unmet medical needs and a cash runway projected into late 2027.
What is Mereo BioPharma Group plc's lead drug candidate?
Mereo BioPharma Group plc's most advanced tracked candidate is alvelestat (Phase 3) for Severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Who is the CEO of Mereo BioPharma Group plc?
Dr. Denise Vera Scots-Knight Ph.D. is the chief executive officer of Mereo BioPharma Group plc (MREO).
Where is Mereo BioPharma Group plc headquartered?
Mereo BioPharma Group plc (MREO) is headquartered in London, United Kingdom.
What therapeutic areas does Mereo BioPharma Group plc focus on?
Mereo BioPharma Group plc develops therapies across Oncology, Respiratory, Musculoskeletal, Endocrinology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.